59
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8371 |
ML188
|
Virus Protease; SARS-CoV | Microbiology/Virology |
ML188是一种选择性非共价 SARS-CoV3CLpro 抑制剂,具有抗病毒活性,IC50为 1.5 μM。 | |||
T10898 |
Samuraciclib hydrochloride
ICEC0942 hydrochloride,CT7001 hydrochloride |
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
Samuraciclib hydrochloride (ICEC0942 hydrochloride) 是一种具有选择性,ATP 竞争性和口服活性的CDK7抑制剂,IC50为 41 nM。它以 GI50值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长,具有抗肿瘤作用。 | |||
T8926 |
Salcaprozate sodium
8-(2-羟基苯甲酰胺基)辛酸钠,SNAC |
Others | Others |
Salcaprozate sodium (SNAC) 是口服吸收促进剂,有作为口服形式的肝素和胰岛素递送剂的潜力。它可提高非共价大分子络合引起的亲脂性,从而增加小肠上皮细胞的被动跨细胞渗透。 | |||
T11469 |
GSK-3484862
|
DNA Methyltransferase | Chromatin/Epigenetic |
GSK-3484862 是 有效的 DNA 甲基转移酶 Dnmt1的非共价抑制剂。GSK-3484862 通过诱导 DNA 低甲基化起抗癌作用。GSK-3484862 介导小鼠胚胎干细胞的整体去甲基化。 | |||
T9303 |
MRTX1133
|
Ras | GPCR/G Protein; MAPK |
MRTX1133 是一种 KRAS G12D 抑制剂 (KD=0.2 pM),具有强效性、选择性和非共价性。MRTX1133 对 KRAS G12D 突变的肿瘤具有抑制活性,而对 KRAS 野生型肿瘤无抑制活性。 | |||
T17389 |
AMAS
|
Others | Others |
AMAS 是一种不可裂解的异双功能交联剂,具有 NHS 酯和马来酰亚胺基团,可实现含胺和巯基分子的共价结合。 | |||
T8431 |
JCN037
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
JCN037 是能透过血脑屏障的EGFR 共价抑制剂,对 EGFR、p-wtEGFR 和 pEGFRvⅢ 的IC50值分别为 2.49、3.95 和4.48 nM。 | |||
T11724 |
JNJ-42226314
|
Lipase | Metabolism |
JNJ-42226314 是一种具有高选择性的非共价单酰基甘油脂肪酶 (MAGL) 抑制剂,具有抗伤害作用。JNJ-42226314 通过内源性大麻素-2-丙烯酰甘油(2-AG)在神经病理性疼痛和炎症性疼痛模型中显示出疗效。 | |||
T40292 |
Opnurasib
NVP-JDQ443,JDQ-443,Opnurasib |
Ras | GPCR/G Protein; MAPK |
Opnurasib (JDQ-443) 是一种可口服且具有选择性和有效性的共价 KRAS G12C 抑制剂,具有抗肿瘤活性,可用于研究晚期非小细胞肺癌。 | |||
T8766 |
GOT1 inhibitor-1
GOT1 inhibitor 2c |
Others | Others |
GOT1 inhibitor-1 (GOT1 inhibitor 2c) 是一种新型的、非共价的谷氨酸草酰乙酸转氨酶 1 (GOT1) 抑制剂(IC50:8.2 uM),是一种戊酸衍生物。 它可用于以及胰腺导管腺癌 (PDAC) 。 | |||
T36287 |
Pirtobrutinib
|
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
Pirtobrutinib (LOXO-305) is an advanced BTK inhibitor that displays high selectivity and operates through a non-covalent mechanism. This compound effectively inhibits various BTK C481 substitution mutations, leading to tumor regression in BTK-dependent lymphoma tumors in mouse xenograft models. Furthermore, Pirtobrutinib exhibits remarkable selectivity for BTK, with more than a 300-fold difference compared to 370 other kinases tested. Notably, at a concentration of 1 μM, Pirtobrutinib demonstrat... | |||
T9573 |
GSK3685032
|
DNA Methyltransferase | Chromatin/Epigenetic |
GSK-3685032 是一种非时间依赖、非共价、选择性的、可逆的DNMT1抑制剂,IC50=0.036 μM。它诱导 DNA 甲基化丧失、转录激活和癌细胞生长抑制。 | |||
T5461 |
GNE-6640
|
DUB | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Ubiquitination |
GNE 6640 是一种选择性泛素特异性肽酶 7(USP7)的非共价抑制剂,其对全长USP7、USP7 催化结构域、全长USP43 以及 Ub-MDM2 的IC50值分别为 0.75 μM、0.43 μM、20.3 μM 和 0.23 μM。 | |||
T63098 |
SARS-CoV-2 Mpro-IN-2
|
||
SARS-CoV-2 Mpro-IN-2 是一种选择性的、低细胞毒性的、非共价 Mpro 抑制剂,其 IC50 值为 0.40 μM。SARS-CoV-2 Mpro-IN-2 表现出良好的抗 SARS-CoV-2 作用,其 EC50 值为 1.1 μM。SARS-CoV-2 Mpro-IN-2 能够用于研究 COVID-19。 | |||
T40063 |
CBR-470-1
|
Nrf2 | Immunology/Inflammation |
CBR-470-1 是一种有效的糖酵解磷酸甘油酸激酶1 (PGK1) 抑制剂,通过增加甲基乙二醛的水平来激活 NRF2。 CBR-470-1 是一种非共价的 Nrf2 激活剂,具有神经保护活性,通过激活 Keap1-Nrf2 级联反应来保护 SH-SY5Y 神经元细胞免受 MPP+ 诱导的细胞毒性。 | |||
T72062 |
BI-2865
|
Ras | GPCR/G Protein; MAPK |
BI-2865 是一种非共价的泛-KRAS 抑制剂。BI-2865 可与 KRAS WT、G12C、G12D、G12V 和 G13D 突变体结合,KD 值 分别为 6.9、4.5、32、26、4.3 nM。BI-2865在对 表达 KRAS G12C、G12D 或 G12V 突变体的 BaF3 细胞实验的过程中显示出抗增殖活性 ,平均 IC50值大约为 140 nM。 | |||
T38889 |
Thailanstatin A
|
||
Thailanstatin A 是真核 RNA 剪接抑制剂,IC50为650 nM,通过非共价结合到剪接体的 U2 snRNA 亚复合物的 SF3b 亚单位发挥作用。Thailanstatin A 对多种癌细胞系的抑制显示 nM 级别的 IC50。它与 Trastuzumab 上的赖氨酸结合,可产生“无连接子” ADC。 | |||
T10534 |
BI-4020
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
BI-4020 是一种第四代,口服有效,非共价的 EGFR 酪氨酸激酶抑制剂。BI-4020 表现出对三联突变的 EGFR del19 T790M C797S 突变体 ( BaF3 细胞系,IC50=0.2 nM),双重突变的 EGFR del19 T790M 以及单突变的 EGFR del19 (IC50=1 nM)的抑制剂活性。BI-4020 保留了抑制 EGFR wt 的活性 (IC50=190 nM)。BI-4020 具有高激酶组选择性和良好的 DMPK 性质。 | |||
T11159 |
EGFR-IN-2
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-2 is a non-covalent, mutation-selective and irreversible second-generation EGFR inhibitor. | |||
T69545 |
Mpro 61
|
||
Mpro 61 is a potent non-covalent inhibitor of SARS-CoV-2 main protease. | |||
T14915 |
CDK12-IN-E9
|
CDK | Cell Cycle/Checkpoint |
CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux. It has a weak binding ability to CDK7/CyclinH complex (IC50> 1 μM). | |||
T12621 |
(R)-FT671
|
Others | Others |
(R)-FT671 is the R-isomer of FT671. FT671 is a potent, non-covalent and selective inhibitor of USP7 (IC50 of 52 nM) | |||
T12621L |
FT671
|
DUB | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Ubiquitination |
FT671 is a non-covalent and selective inhibitor of USP7 (IC50: 52 nM) It also binds to the USP7 catalytic domain (Kd: 65 nM). | |||
T10422 |
Avibactam free acid
NXL-104 free acid |
Antibacterial | Microbiology/Virology |
Avibactam (NXL-104) free acid is a covalent and reversible inhibitor of non-β-lactam β-lactamase (IC50s: 8 nM and 5 nM for β-lactamase TEM-1 and CTX-M-15). | |||
T19568 |
Sulfo-SMPB sodium
|
Others | Others |
Sulfo-SMPB sodium is a non-cleavable heterobifunctional chemical cross-linking reagent that combines N-hydroxysuccinimide ester and maleimide groups. This compound enables the covalent conjugation of molecules possessing amine and sulfhydryl functionalities. | |||
T63800 | ZM223 hydrochloride | ||
ZM223 hydrochloride 是有效的、非共价的、口服具有活力的 NEDD8 活化酶 (NAE) 抑制剂。 | |||
T13412L |
ZM223 hydrochloride (2031177-48-5 free base)
ZM223 hydrochloride |
Serine Protease | Proteases/Proteasome |
ZM223 hydrochloride is an orally active, potent non-covalent inhibitor of NEDD8 activating enzyme (NAE), and with excellent anticancer activity. | |||
T73510 | ZG1077 | ||
ZG1077 是一种共价的KRAS G12C 抑制剂。ZG1077 可用于非小细胞肺癌 (NSCLC) 的研究。 | |||
T40358 |
Ensitrelvir fumarate
S-217622 fumarate |
||
Ensitrelvir (S-217622) fumarate is a novel orally active inhibitor, targeting the SARS-CoV-2 3CL protease (IC50 = 13 nM). It demonstrates non-covalent and non-peptidic characteristics. This compound represents a pioneering advancement in the development of effective antiviral agents against the SARS-CoV-2 virus. | |||
T39648 |
(R)-GSK-3685032
|
||
(R)-GSK-3685032 is the R-enantiomer of GSK-3685032. GSK-3685032 is a first-in-class, non-time-dependent, non-covalent, reversible, selective DNMT1 inhibitor with an IC 50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation and inhibition of cancer cell growth. | |||
T39859 | ARN19689 | ||
ARN19689 is an effective inhibitor of human NAAA, demonstrating high potency in the low nanomolar range (IC 50 = 0.042 μM). The compound acts through a non-covalent mechanism, highlighting its ability to interact with the enzyme for inhibition. | |||
T35844 |
(R)-Pirtobrutinib
|
||
(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib, and Pirtobrutinib is a highly selective and non-covalent next generation BTK inhibitor. Pirtobrutinib (LOXO-305) effectively inhibits diverse BTK C481 substitution mutations[1]. | |||
T26827 |
Bisnorcymserine
N1 N8 Bisnorcymserine,N1N8Bisnorcymserine,N1-N8-Bisnorcymserine |
||
Bisnorcymserine is a reversible inhibitor of butyrylcholinesterase. The leaving group, bisnoreseroline, interacts in a non-covalent way with Ser(200) and His(440), disrupting the existing interactions within the catalytic triad, and it stacks with Trp(84) | |||
T82137 | IA1-8H2 | ||
IA1-8H2是一种PHPT1的非共价、非竞争性抑制剂,具有3.4 μM的IC50。该化合物在肺癌、肝癌、肾癌等多种癌症的研究中有应用潜力。 | |||
T75255L | SB-435495 hydrochloride | ||
SB-435495 hydrochloride,一种有效的、选择性的、可逆性非共价口服Lp-PLA2抑制剂,IC50值为0.06 nM。 | |||
T39430 |
XMU-MP-3
|
||
XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis. | |||
T37085 |
Luxeptinib
|
||
Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4]. | |||
T79344 |
CDD-1819
|
SARS-CoV | Microbiology/Virology |
CDD-1819为非共价、非肽类SARS-CoV-2 Mpro有效抑制剂,其Ki值为5 nM。该化合物同样抑制ΔP168、A173V及ΔP168/A173V Mpro突变体。 | |||
T75255L1 | SB-435495 ditartrate | ||
SB-435495 ditartrate,一种口服有效的Lp-PLA2抑制剂,特点为高效、选择性、可逆且非共价,IC50值为0.06 nM。 | |||
T79345 |
CDD-1733
|
SARS-CoV | Microbiology/Virology |
CDD-1733是SARS-CoV-2 Mpro的非共价非肽抑制剂,具有12 nM的Ki值。该化合物也能够抑制ΔP168、A173V及ΔP168/A173V Mpro突变体。 | |||
T79346 |
CDD-1845
|
SARS-CoV | Microbiology/Virology |
CDD-1845,一种非共价非肽类SARS-CoV-2 Mpro抑制剂,具有3 nM的Ki值。该化合物同样能抑制ΔP168、A173V及ΔP168/A173V的Mpro突变体。 | |||
T75109 |
HECT E3-IN-1
|
||
HECT E3-IN-1 (compound 3) 为HECT E3 连接酶的抑制剂,其作用机制为破坏Nedd4-1 的非共价Ub结合位点与Ub的结合。 | |||
T75255 |
SB-435495
|
||
SB-435495 是一种有效的、选择性的、可逆的、非共价的、具有口服活性的 Lp-PLA2抑制剂,IC50为 0.06 nM。 | |||
T9671 | X77 | ||
X77 是 SARS-CoV-2 主要蛋白酶 (SARS-CoV-2 Mpro) 的有效非共价键抑制剂。X77 与 SARS-CoV-2 Mpro 结合,Kd 值为 0.057 μM。 | |||
T74849 | EBL-3183 | ||
EBL-3183为一种吲哚-2-羧酸盐,作为有效的金属-β-内酰胺酶(MBL)抑制剂。它通过可逆结合、非共价及竞争性作用抑制NDM-1,其pIC50值为7.7。 | |||
T81849 | MAT-POS-e194df51-1 | SARS-CoV | Microbiology/Virology |
MAT-POS-e194df51-1 是一种非共价、非肽类、口服活性的SARS-CoV-2主蛋白酶 (Mpro) 抑制剂,IC50 值达 37nM。该化合物展现细胞毒性,其在 A549-ACE2-TMPRSS2 和 HeLa-ACE2 细胞线上的 EC50 值分别为 64 nM 和 126 nM。 | |||
T72762 | Proteasome-IN-4 | ||
Proteasome-IN-4 是一种良好的非共价 proteasome 抑制剂 (IC50= 8.39 nM)。Proteasome-IN-4 对 RPMI-8226、MM-1S 和 MV-4-11 细胞系具有较强的抗增殖活性。Proteasome-IN-4 可用于癌症研究。 | |||
T79050 |
JBI-589
|
||
JBI-589为一种非共价、选择性PAD4抑制剂,可降低CXCR2表达,阻断中性粒细胞趋化性;此外,JBI-589能减小原发肿瘤体积及其转移,并增强检查点抑制剂的抗肿瘤效果。 | |||
T63920 | LSD1-IN-19 | ||
LSD1-IN-19 (compound 29) 是一种选择性的、有效的、非共价的 LSD1 抑制剂 (Ki: 0.108 μM, KD: 0.068 μM)。LSD1-IN-19 在 THP-1 白血病细胞和 MDA-MB-231 乳腺癌细胞中具有抗增殖效果,其72h 的IC50值分别为 0.17 和 0.40 μM。 | |||
T81202 |
SARS-CoV-2-IN-69
|
SARS-CoV | Microbiology/Virology |
SARS-CoV-2-IN-69 (Compound 7E)是一种SARS-CoV-2的非共价抑制剂,具有7.4 μM的EC50值。它有效针对SARS-CoV-2的主蛋白酶(Mpro)并作为木瓜蛋白酶(PLpro)的非共价抑制剂。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8307 |
Hydroxy-α-sanshool
羟基-α-山椒素,Hydroxy-α-sanshool |
Endogenous Metabolite; TRP/TRPV Channel | Membrane transporter/Ion channel; Metabolism |
Hydroxy-α-sanshool 是分离自胡椒的烷基酰胺,作为 TRPA1的共价激动剂和 TRPV1的非共价激动剂,EC50分别为69和 1.1 µM。 |